Vaccine Strategies for Endemic Fungal Pathogens

Vaccine Strategies for Endemic Fungal Pathogens

March 5-6, 2019

5601 Fishers Lane, Rockville, MD, 1D13

Day 1

Time

Session/Topic

Speaker/Moderator

Welcome, introductions, workshop objectives

7:00-8:00

Registration

 

8:00-8:05

Introduction

Emily Erbelding, MD, MPH

NIAID/NIH

8:058:10

Opening Remarks

Dennis Dixon, PhD

NIAID/NIH

8:10-8:15

Workshop Objectives and NIAID Mycology Portfolio

Dona Love, PhD

NIAID/NIH

Session 1: Endemic mycoses and the potential for vaccines

8:15-8:40

Keynote Presentation:

Defending against the Endemic Systemic Mycoses: Advances, Challenges and Opportunities

Bruce Klein_, MD

University of Wisconsin

8:40-9:05

Vaccines to Prevent Coccidioidomycosis:

60 Years and Counting

John Galgiani, MD

University of Arizona, Valley Fever Center for Excellence

9:05-9:20

The Role of Patients and Nonprofits in Awareness and Advocacy

Rob Purdie

Patient Advocate

9:20-9:35

The Valley Fever Institute at Kern Medical

Challenges in a Coccidiodal Vaccine Development

Royce Johnson, MD, FACP

Kern Medical

9:35-10:00

Moderated panel discussion of Session 1

Moderator: Royce Johnson, MD, FACP

Kern Medical

10:00-10:15

Coffee break

 

Session 2: Epidemiological insights to facilitate vaccine development

10:15-10:40

Overview of Endemic Mycoses

Tom Chiller, MD, MPHTM

Centers for Disease Control and Prevention (CDC)

10:40 -11:05

Update in Histoplasmosis and Blastomycosis Epidemiology

Brendan Jackson, MD, MPH

Epidemiology Team Lead, Mycotic Diseases Branch (MDB), Centers for Disease Control and Prevention (CDC)

11:05-11:30

Endemic Mycoses in Asia

Thuy Le , MD, PhD

Duke University School of Medicine

11:30-11:55

Epidemiology of Coccidioidomycosis in the United States: With New Insights from the Southern California Experience

Sara Tartof, PhD, MPH

Kaiser Permanente Southern California

11:55-12:10

Moderated panel discussion of Session 2

Moderator: Peter G. Pappas, MD, FACP

University of Alabama at Birmingham

12:10-1:15

Lunch

 

Session 3: Protective immune response to endemic mycoses

1:15-1:40

Host Defense Against Dimorphic Fungal Pathogens: Critical Lessons from Inherited and Acquired Human Immunodeficiencies

Mihalis Lionakis, MD, ScD

NIAID/NIH

1:40-2:05

Eng2: a novel antifungal adjuvant and antigen and its mechanism of protection

Marcel Wuethrich, PhD

University of Wisconsin

2:05 -2:30

Immunity to Valley Fever: Of Mice and Men

Joshua Fierer, MD

Professor of Medicine and Pathology UC San Diego and Chief of Infectious Diseases, VA San Diego

2:30 -2:55

Adjuvants for Fungal Vaccines

Jay Evans, PhD

University of Montana

2:55-3:15

Moderated panel discussion of Session 3

Moderator: Jack Edwards, MD

Los Angeles Biomedical Research Institute at Harbor/UCLA

3:15-3:30

Coffee Break

 

Session 4: Correlates of protection and molecular markers of infection

3:30-3:55

Speciation of Coccidioides and Potential Biomarkers

Bridget Barker, PhD

Northern Arizona University

3:55-4:20

Diagnostics for Coccidioidomycosis

George Thompson III, MD

University of California, Davis

4:20-4:45

Markers of Protective Immunity in Human Coccidioidomycosis

Neil Ampel, MD

Professor Emeritus of Medicine, University of Arizona

4:45-5:05

Moderated panel discussion of Session 4

Sarah Browne, MD

OVRR/CBER/FDA

End of Day 1

 

Day 2

Session 5: Preclinical vaccine development

Time

Session/Topic

Speaker/Moderator

8:30-8:55

Keynote presentation:

Designing and Building the Next Generation of Vaccine Adjuvants

Derek O’Hagan, PhD

GlaxoSmithKline

8:55-9:20

Vaccination with Fungal Antigens Delivered in Glucan Particles: Preclinical Models with Endemic and Nonendemic Cryptococcus

Stuart Levitz, MD

Professor of Medicine and Microbiology and Physiological Systems, University of Massachusetts Medical School

9:20-9:45

Evaluation of Immune Response and Cross-Protective Efficacy of a Recombinant Vaccine Against Both Species of Coccidioides

Chiung Yu Hung, PhD

Assistant Professor of Microbiology and Immunology, University of Texas at San Antonio

9:45-10:10

A Live, Avirulent Vaccine for Coccidioidomycosis in Dogs

Lisa Shubitz, DVM

University of Arizona, Valley Fever Center for Excellence

10:10-10:30

Moderated panel discussion of Session 5

Moderator: Joshua Nosanchuk, MD

Albert Einstein College of Medicine

10:30-10:45

Coffee Break

 

Session 6: Commercial path for fungal vaccines

10:45-11:10

Considerations for Vaccine Development

Sarah Browne, MD

OVRR/CBER/FDA

11:10-11:35

Update on Cross-Kingdom Vaccine:

Scientific and Developmental Challenges

Jack Edwards, MD

Los Angeles Biomedical Research Institute at Harbor/UCLA

11:35-12:00

NIAID Support for Vaccine Development

Erin Zeituni, PhD

NIAID/NIH

12:00-12:20

Moderated panel discussion of Session 6

B.F. “Lee” Hall, MD, PhD, FIDSA

NIAID/NIH

End of Meeting

 

 

Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!
MSN MSN
Top